News

Goldman Sachs Reaffirms Strong Buy Rating for Domino's Pizza

Goldman Sachs Reaffirms Strong Buy Rating for Domino's Pizza

Goldman Sachs Maintains Optimism for Domino's Pizza

Goldman Sachs has reaffirmed its positive outlook on Domino's Pizza shares (NYSE: DPZ), maintaining a Buy rating with a projected price target of $515.00. Despite a slight lag in recent performance, the firm remains confident in the brand's potential to dominate the pizza market.

Recent Performance Highlights

Domino's has recently reported U.S. same-store sales growth (SSSG) of +3.0%, falling short of expectations which anticipated a growth of 3.5%. Internationally, SSSG mirrored this trend with a reported growth of +0.8%, missing the consensus projection of +2.8%. These statistics prompted a brief decline in Domino's stock, which dipped by 1.1%, in contrast to a milder drop in the broader S&P 500 index by 0.2%.

Growth Projections and Market Position

Goldman Sachs's confidence is bolstered by expectations for robust growth. The firm predicts a compound annual growth rate (CAGR) of 7.1% in sales and 12.2% in earnings per share from 2023 to 2026. Such growth reflects Domino's potential to enhance its market share against both direct competitors and other fast-food entities.

Analyst Adjustments and Ratings

Recent evaluations have prompted several financial institutions to revisit their price targets for Domino's shares. Notably, Wells Fargo, Stifel, and Barclays have all lowered their targets, with estimates now at $420, $470, and $370, respectively. Despite these downward adjustments, all firms retained their positive ratings on the stock, highlighting ongoing faith in Domino’s fundamentals.

Third-Quarter Results Analysis

In its latest third-quarter results, Domino's announced a 3% increase in U.S. same-store sales, which fell short of the projected 3.6% increase. Similarly, the international market experienced a growth of only 0.8%, below the anticipated 2.9%. Consequently, Domino's has adjusted its annual global retail sales growth forecast down to 6%, reflecting a more cautious outlook.

Earnings Performance and Strategic Initiatives

On a brighter note, Domino's third-quarter earnings per share reached $4.19, exceeding the Analyst's expectations of $3.65 despite the modest sales growth performance. Following this announcement, Stephens held steady with an Equal Weight rating, while RBC Capital initiated coverage with an Outperform rating.

Future Growth Drivers

Looking ahead, Domino's aims to stimulate growth through strategic promotions and enhancing partnerships with third-party delivery services like DoorDash and Uber. The anticipated launch of its EP 2.0 initiative is also expected to play a critical role in boosting sales for the fourth quarter.

Financial Stability and Investment Insights

Goldman Sachs’ bullish perspective is further supported by InvestingPro data. As of now, Domino's boasts a market capitalization of $14.3 billion and a P/E ratio of 25.4. This strong valuation suggests investors are willing to pay a premium for Domino's stock, reinforcing Goldman Sachs’ positive forecast.

Dividend History and Asset Management

Domino's shows a commendable dividend history, having raised its dividend for 11 consecutive years while maintaining payments for 13 years. This solid performance indicates the company's commitment to returning value to shareholders, which is particularly appealing to income-focused investors. Additionally, with liquid assets that comfortably exceed short-term obligations, Domino's retains a strong financial footing to support ongoing growth strategies.

Considerations for Investors

However, investors should consider that Domino's stock is currently trading at high EBITDA and revenue valuation multiples. This necessitates careful evaluation alongside Goldman’s optimistic price targets. The firm's expectations align closely with the company’s recent revenue growth of 2.28% over the last twelve months, and a robust 7.14% in the latest quarter, indicating solid overall market performance.

Frequently Asked Questions

What is Goldman Sachs' rating on Domino's Pizza stock?

Goldman Sachs currently maintains a Buy rating on Domino's Pizza with a target price of $515.00.

How did Domino's perform in the latest quarter?

In its most recent quarter, Domino's reported a 3% increase in U.S. same-store sales and an earnings per share of $4.19.

What adjustments have other analysts made to Domino's price targets?

Wells Fargo, Stifel, and Barclays have all lowered their price targets for Domino's shares to $420, $470, and $370 respectively, while maintaining their ratings.

What strategies is Domino's using for future growth?

Domino's plans to drive growth through strategic promotions, partnerships with delivery services, and the upcoming launch of its EP 2.0 initiative.

How does the financial position of Domino's support its outlook?

Domino's strong market capitalization and solid dividend history indicate a strong financial foundation, reinforcing Goldman Sachs' optimistic projections for the company.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles